CA2289202A1 - Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent - Google Patents

Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent Download PDF

Info

Publication number
CA2289202A1
CA2289202A1 CA002289202A CA2289202A CA2289202A1 CA 2289202 A1 CA2289202 A1 CA 2289202A1 CA 002289202 A CA002289202 A CA 002289202A CA 2289202 A CA2289202 A CA 2289202A CA 2289202 A1 CA2289202 A1 CA 2289202A1
Authority
CA
Canada
Prior art keywords
therapeutic agent
sae
pharmaceutical formulations
sulfoalkyl ether
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002289202A
Other languages
French (fr)
Other versions
CA2289202C (en
Inventor
Valentino K. Stella
James Mcginity
Roger A. Rajewski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cydex Pharmaceuticals Inc
Original Assignee
Cydex Inc.
Valentino K. Stella
James Mcginity
Roger A. Rajewski
The University Of Kansas
Cydex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cydex Inc., Valentino K. Stella, James Mcginity, Roger A. Rajewski, The University Of Kansas, Cydex Pharmaceuticals, Inc. filed Critical Cydex Inc.
Publication of CA2289202A1 publication Critical patent/CA2289202A1/en
Application granted granted Critical
Publication of CA2289202C publication Critical patent/CA2289202C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

Sulfoalkyl ether-cyclodextrin (SAE-CD) based pharmaceutical formulations are provided by the present invention. These formulations comprise SAE-CD derivatives and a therapeutic agent, a major portion of which is not complexed to the SAE-CD. The present formulations are advantageously easier to prepare than other SAE-CD based formulations in the art yet provide similar or improved effectiveness. The SAE-CD derivative can be used to modify the bioavailability and/or rate of bioabsorption of therapeutic agents.
CA002289202A 1997-05-05 1998-04-20 Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent Expired - Lifetime CA2289202C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/851,006 1997-05-05
US08/851,006 US5874418A (en) 1997-05-05 1997-05-05 Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
PCT/US1998/008221 WO1998050077A1 (en) 1997-05-05 1998-04-20 Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent

Publications (2)

Publication Number Publication Date
CA2289202A1 true CA2289202A1 (en) 1998-11-12
CA2289202C CA2289202C (en) 2005-03-15

Family

ID=25309709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002289202A Expired - Lifetime CA2289202C (en) 1997-05-05 1998-04-20 Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent

Country Status (10)

Country Link
US (1) US5874418A (en)
EP (1) EP0980262B1 (en)
JP (1) JP3745382B2 (en)
KR (1) KR100378031B1 (en)
AT (1) ATE234634T1 (en)
AU (1) AU729671B2 (en)
CA (1) CA2289202C (en)
DE (1) DE69812343T2 (en)
ES (1) ES2190075T3 (en)
WO (1) WO1998050077A1 (en)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
AU775037B2 (en) * 1998-12-09 2004-07-15 Eli Lilly And Company Pellet implant system
NZ503538A (en) * 1997-09-25 2001-03-30 Bayer Ag Moxifloxacin formulation characterised by the release times containing hydroxypropylmethylcellulose or polyvinylpyrrolidone as binder and ethylcellulose as film forming polymer
JP2001518500A (en) * 1997-10-03 2001-10-16 ワーナー−ランバート・カンパニー Compressed nitroglycerin tablets and method of making same
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6645192B2 (en) * 1998-09-30 2003-11-11 Ivy Animal Health, Inc. Pellet implant system for immediate and delayed release of antiparasitic drug
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6245352B1 (en) * 1999-04-27 2001-06-12 Eli Lilly And Company Pharmaceutical formulation
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
BR0013719A (en) * 1999-09-02 2002-07-23 Nostrum Pharmaceuticals Inc Controlled-release oral dosage, suitable for oral administration
DE19941769A1 (en) * 1999-09-02 2001-03-08 Beiersdorf Ag Cosmetic or dermatological active agent combination of cyclodextrin and biotin compound, useful in care or protection of skin, e.g. for treatment or prevention of aging symptoms or photodermatosis
US6346231B1 (en) * 1999-10-06 2002-02-12 Joar Opheim Flavored gelatin capsule and method of manufacture
US6294013B1 (en) * 1999-12-08 2001-09-25 Sun Chemical Corporation Polysaccharide pigment dispersions
US20030148996A1 (en) * 2000-03-31 2003-08-07 Joseph Rubinfeld Camptothecin complexes
WO2001080826A2 (en) * 2000-04-20 2001-11-01 Bristol-Myers Squibb Company Taste masking coating composition
US6858584B2 (en) 2000-05-02 2005-02-22 Theravance, Inc. Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
US6953586B1 (en) 2000-06-08 2005-10-11 Ivy Animal Health, Inc. Growth promoting pharmaceutical implant
PE20020300A1 (en) * 2000-08-22 2002-05-10 Pharmacia Corp COMPOSITION OF SOLUTION OF AN ANTIBIOTIC DRUG BASED ON OXAZOLIDINONE WITH IMPROVEMENT OF DRUG LOAD
PE20020578A1 (en) 2000-10-10 2002-08-14 Upjohn Co A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
IN190699B (en) * 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
DE10114245A1 (en) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Production and use of an antibiotic / antibiotic preparation
DE10114364A1 (en) * 2001-03-22 2002-10-02 Heraeus Kulzer Gmbh & Co Kg Process for the production of antibiotic composites
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003028718A1 (en) * 2001-10-01 2003-04-10 Smithkline Beecham Corporation Novel formulations of carvedilol
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
JP2005515996A (en) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド Pharmaceutical composition comprising active vitamin D compound
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
RU2004123637A (en) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) PHARMACEUTICAL MEDICINAL FORMS OF CONTROLLED RELEASE OF THE CHOLESTEROL PROTEIN PROTEIN INHIBITOR
EP1478404A1 (en) * 2002-02-22 2004-11-24 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
EP1476135A1 (en) * 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US20040034099A1 (en) * 2002-06-27 2004-02-19 Ramsey Beverly J. Pharmaceutical composition
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd Transdermal delivery system for anti-emetic medication
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd Transdermal delivery system for water insoluble drugs
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2004087121A2 (en) * 2003-03-28 2004-10-14 Azaya Therapeutics, Inc. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
ATE446581T1 (en) * 2004-03-12 2009-11-15 Trinity College Dublin MAGNETORRESISTIVE MEDIUM
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
WO2005105827A2 (en) 2004-04-15 2005-11-10 Proteolix, Inc. Compounds for proteasome enzyme inhibition
CN101098678A (en) * 2004-04-23 2008-01-02 锡德克斯公司 Dpi formulation containing sulfoalkyl ether cyclodextrin
AU2013201437B2 (en) * 2004-04-23 2015-09-03 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
AU2015255259B2 (en) * 2004-04-23 2017-07-27 Cydex Pharmaceuticals, Inc DPI formulation containing sulfoalkyl ether cyclodextrin
EP1758921A2 (en) * 2004-05-10 2007-03-07 Proteolix, Inc. Compounds for proteasome enzyme inhibition
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
BRPI0513455A (en) * 2004-07-22 2008-05-06 Pfizer Prod Inc flavor masking formulation comprising the drug in a delayed dissolution form and / or cyclodextrin in an improved dissolution form
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
DE602005026556D1 (en) * 2004-12-07 2011-04-07 Proteolix Inc COMPOSITION FOR PROTEASOME INHIBITION
US20060128653A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
US20060128654A1 (en) * 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
US20060183725A1 (en) * 2005-02-15 2006-08-17 Thomas Graeser Pharmaceutical preparation for oral contraception
DK2581078T3 (en) 2005-10-26 2015-03-02 Cydex Pharmaceuticals Inc Sulfoalkylætercyclodekstrinsammensætninger and processes for the preparation thereof
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
AU2011204957B2 (en) * 2005-10-26 2013-12-05 Cydex Pharmaceuticals, Inc Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
NZ595196A (en) 2005-11-09 2013-03-28 Proteolix Inc Peptide-based compounds for enzyme inhibition
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
WO2007075801A2 (en) * 2005-12-20 2007-07-05 Tika Läkemedel Ab Method and system for the delivery of corticosteroids having an enhanced pharmacokinetic profile
EP1988878A2 (en) * 2006-02-15 2008-11-12 Tika Läkemedel AB Sterilization of corticosteroids with reduced mass loss
US20080069889A1 (en) * 2006-03-07 2008-03-20 Cherukuri S R Compressible resilient granules and formulations prepared therefrom
NZ573759A (en) 2006-06-19 2012-03-30 Proteolix Inc Peptide epoxyketones for proteasome inhibition
US8639782B2 (en) 2006-08-23 2014-01-28 Ebay, Inc. Method and system for sharing metadata between interfaces
PL2061458T3 (en) * 2006-09-15 2015-07-31 Univ Minnesota Topiramate compositions and methods for their use
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
EP2061587A1 (en) * 2007-04-26 2009-05-27 Sigmoid Pharma Limited Manufacture of multiple minicapsules
EP3766493B1 (en) 2007-04-27 2023-08-23 CyDex Pharmaceuticals, Inc. Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2008148080A2 (en) * 2007-05-24 2008-12-04 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin]
CN101686931B (en) * 2007-06-06 2013-06-19 巴斯夫欧洲公司 Pharmaceutical formulation for the production of chewable tablets and lozenges
EP2164462B1 (en) * 2007-06-06 2017-05-31 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
ES2493641T3 (en) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Nasal administration of aqueous corticosteroid solutions
EP2207791B2 (en) * 2007-10-04 2019-08-07 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2010014617A1 (en) * 2008-07-28 2010-02-04 University Of Kansas Heat shock protein 90 inhibitor dosing methods
UA104600C2 (en) 2008-10-21 2014-02-25 Онікс Терап'Ютікс, Інк. Combination therapy with peptide epoxyketones
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
MA32931B1 (en) 2008-11-15 2012-01-02 Rib X Pharmaceuticals Inc ANTIMICROBIAL COMPOSITIONS
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
AR075899A1 (en) 2009-03-20 2011-05-04 Onyx Therapeutics Inc PROTEASA INHIBITING CRYSTALLINE EPOXYCETON TRIPEPTIDES
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
KR20190071006A (en) 2009-05-13 2019-06-21 사이덱스 파마슈티칼스, 인크. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
CN106389307A (en) 2009-05-29 2017-02-15 锡德克斯药物公司 Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
BRPI1010739A2 (en) 2009-06-16 2016-03-15 Bristol Myers Squibb Co dosage forms of apixaban.
WO2011041593A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
JP5919196B2 (en) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Use of peptide epoxy ketones for metastasis inhibition
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
EP2538923A2 (en) 2010-02-22 2013-01-02 Lupin Limited Taste-masked powder for suspension compositions of methylprednisolone
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR20130094185A (en) 2010-04-07 2013-08-23 오닉스 세라퓨틱스, 인크. Crystalline peptide epoxyketone immunoproteasome inhibitor
US20130230586A1 (en) 2010-10-02 2013-09-05 Link Research & Grants Corporation Treatment of Tinnitus and Related Auditory Dysfunctions
CA2816319C (en) 2010-11-01 2020-06-30 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
TWI544922B (en) * 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
KR20140078619A (en) 2011-09-18 2014-06-25 유로-셀띠끄 소시에떼 아노님 Pharmaceutical compositions
RU2019104004A (en) 2012-01-23 2019-03-07 Сейдж Терапьютикс, Инк. MEDICINAL FORMS OF NEUROACTIVE STEROIDS AND METHODS OF TREATING CNS DISORDERS
AR092790A1 (en) 2012-02-01 2015-05-06 Euro Celtique Sa BENCIMIDAZOLIC DERIVATIVES OF HYDROXAMIC ACID
EP2814849B8 (en) 2012-02-15 2020-03-04 CyDex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
RU2747757C2 (en) 2012-02-28 2021-05-13 Сидекс Фармасьютикалс, Инк. Compositions of alkylated cyclodextrin and methods of their preparation and application
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
EP2887944B1 (en) 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
MY181829A (en) 2012-10-22 2021-01-08 Cydex Pharmaceuticals Inc Alkylated cyclodextrin compositions and processes for preparing and using the same
GB201312737D0 (en) * 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
EP3166642B1 (en) 2014-06-18 2020-06-03 Audevard Transdermal formulations of pergolide and uses thereof
PT3183295T (en) 2014-08-22 2023-11-03 Cydex Pharmaceuticals Inc Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
JOP20200195A1 (en) 2014-09-08 2017-06-16 Sage Therapeutics Inc Neuroactive steroids, compositions, and uses thereof
CA2974123C (en) 2015-02-02 2023-08-01 Mei Pharma, Inc. Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy
US10702568B2 (en) 2015-03-19 2020-07-07 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
US20190365720A1 (en) 2016-11-18 2019-12-05 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. Oral testosterone undecanoate therapy
BR112019023074A2 (en) 2017-05-03 2020-06-09 Cydex Pharmaceuticals Inc composition containing cyclodextrin and busulfan
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
US20200276209A1 (en) 2017-09-11 2020-09-03 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
EP4010031A1 (en) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Processes of preparing polyglutamated antifolates and uses of their compositions
AU2021291071A1 (en) 2020-06-18 2023-02-23 Halo Therapeutics Ltd Fatty acid complexes of coronavirus spike protein and their use
WO2022029334A1 (en) 2020-08-07 2022-02-10 Gbiotech S.À.R.L. Combination therapies for treating coronavirus infection
CN114128914B (en) * 2021-12-02 2023-02-10 云南中烟工业有限责任公司 Clathrate compound, preparation method and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (en) * 1970-06-10 1975-02-04
ZA82447B (en) * 1981-01-23 1983-09-28 Wellcome Found Chemical complex
JPS58177949A (en) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd Clathrate compound of lankacidin-group antibiotic substance
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0146841A3 (en) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Water soluble mixed ether of beta-cyclodextrin, and process for its preparation
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH0651725B2 (en) * 1985-02-28 1994-07-06 メルシャン株式会社 Partially methylated cyclodextrin and method for producing the same
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (en) * 1986-12-26 1996-02-28 日清製粉株式会社 Sustained-release pharmaceutical preparation
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Also Published As

Publication number Publication date
JP2002503267A (en) 2002-01-29
WO1998050077A1 (en) 1998-11-12
KR100378031B1 (en) 2003-04-16
US5874418A (en) 1999-02-23
JP3745382B2 (en) 2006-02-15
AU729671B2 (en) 2001-02-08
CA2289202C (en) 2005-03-15
KR20010012233A (en) 2001-02-15
ES2190075T3 (en) 2003-07-16
AU7153598A (en) 1998-11-27
EP0980262B1 (en) 2003-03-19
ATE234634T1 (en) 2003-04-15
DE69812343T2 (en) 2004-04-01
EP0980262A1 (en) 2000-02-23
DE69812343D1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
NZ512692A (en) Sulphoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
CA2119154A1 (en) Derivatives of Cyclodextrins Exhibiting Enhanced Aqueous Solubility and the Use Thereof
RU94028890A (en) COMPOSITIONS OF DERIVATIVES OF CYCLODEXTRIN, COMPOSITIONS, CONTAINING MEDICINES AND DERIVATIVES OF CYCLODEXTRINS
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
IL149163A0 (en) Piperazine derivatives of carbazole, their preparation and pharmaceutical compositions containing them
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
AU691476B2 (en) Injectable taxane derivative based compositions
GB9409778D0 (en) Compositions
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
HUP0302086A2 (en) Oral pharmaceutical composition with a delayed action and process for its preparation
AU5309794A (en) Pharmaceutical compositions containing nanocapsules
UA66861C2 (en) 2-phenyl-1-[4-(2-aminoeihoxy)benzyl]-indole in combination with estrogens, method for treatment and pharmaceutical product
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
PL346764A1 (en) New oral formulation for 5-ht4
CZ16395A3 (en) Inclusion complexes of nimesulid salts of alkali metals and alkaline earth metals with cyclodextrins, process of their preparation and pharmaceutical compositions containing thereof
EP0931545A3 (en) Droloxifene pharmaceutical compositions
EA200100674A1 (en) CLEDRATES DEHYDROEPIANDROSTERONE AND RELATED PHARMACEUTICAL COMPOSITIONS
AU1572301A (en) Cyclopentyl sulfonamide derivatives
DE69612056D1 (en) TERPEN DERIVATIVES (SARCODICTYINE) AS AN ANTICRECELLENT
GEP20043377B (en) Pharmaceutical Complex
HUP0300185A2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
HUP0202621A2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
MX9601852A (en) Estramustine formulations with improved pharmaceutical properties.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180420